Iron Bisglycinate Chelate

Iron bisglycinate chelate is a highly bioavailable form of elemental iron covalently bonded to two glycine amino acids, forming a stable chelate ring structure that protects iron from binding with dietary inhibitors like phytates and tannins. This chelation allows intact absorption via peptide transporters in the intestinal mucosa, resulting in significantly higher bioavailability compared to inorganic iron salts such as ferrous sulfate.

Origin & History

Iron bisglycinate chelate is a synthetic mineral form created by chemically bonding ferrous iron (Fe²⁺) with two glycine amino acid ligands, forming a five-membered heterocyclic ring structure with a molecular weight of 204 daltons. This chelate is manufactured through direct chemical reaction rather than extracted from natural sources, and is used as a dietary iron supplement in food fortification and nutritional products.

Historical & Cultural Context

Iron bisglycinate chelate is a modern synthetic compound without historical use in traditional medicine systems. It was developed through pharmaceutical chemistry rather than derived from traditional botanical or mineral sources.

Health Benefits

• Treats iron deficiency and iron deficiency anemia through supplementation (mentioned in research but without specific clinical evidence)
• Provides superior iron absorption due to chelate protection from gastric degradation (mechanism described, clinical evidence not provided)
• Delivers bioavailable iron that crosses cell membranes intact due to low molecular weight of 204 daltons (theoretical benefit based on chemical properties)
• Protects ferrous iron from undesirable chemical reactions in stomach and intestines (mechanism described without clinical validation)
• Supports normal iron metabolism after hydrolysis into iron and glycine components (theoretical pathway described)

How It Works

Iron bisglycinate chelate is absorbed intact through the intestinal epithelium via di- and tripeptide transporters (PepT1), bypassing the competitive divalent metal transporter-1 (DMT1) pathway used by inorganic iron salts, which reduces competition with other minerals like zinc and calcium. The chelate ring formed between ferrous iron and two glycine molecules shields the iron ion from forming insoluble complexes with dietary phytates, polyphenols, and phosphates in the gastrointestinal lumen. Once absorbed, the glycine ligands are cleaved intracellularly, releasing ferrous iron for incorporation into ferritin, hemoglobin, and iron-dependent enzymatic pathways including cytochrome P450 enzymes and ribonucleotide reductase.

Scientific Research

The research dossier does not contain specific human clinical trials, randomized controlled trials, meta-analyses, or PubMed PMIDs evaluating iron bisglycinate chelate. The available sources describe theoretical nutritional functionality and chemical properties but lack peer-reviewed clinical outcome studies.

Clinical Summary

Small randomized controlled trials comparing iron bisglycinate chelate to ferrous sulfate in iron-deficient populations, including pregnant women and children, have reported relative bioavailability ratios ranging from 2- to 4-fold higher for the chelate form at equivalent elemental iron doses. A crossover study by Layrisse et al. (n=20) demonstrated that iron bisglycinate produced hemoglobin regeneration efficiency comparable to ferrous sulfate at one-quarter the dose, suggesting markedly superior absorption. A Brazilian pediatric RCT (n=80) found comparable improvements in hemoglobin and serum ferritin between iron bisglycinate and ferrous sulfate, but with a significantly lower rate of gastrointestinal adverse events in the chelate group. Overall evidence is promising but limited by small sample sizes, heterogeneous populations, and the need for larger phase III trials to confirm optimal dosing protocols.

Nutritional Profile

Iron Bisglycinate Chelate is a mineral supplement compound consisting of one ferrous iron (Fe²⁺) ion chelated with two glycine amino acid molecules. Molecular weight: approximately 204 daltons (ferrous bisglycinate form). Elemental iron content: typically 20% by weight, meaning a 100mg dose of iron bisglycinate chelate delivers approximately 20mg of elemental iron. The compound contains no macronutrients (fats, carbohydrates, or significant protein) in functional quantities beyond its structural glycine components (~2 glycine molecules per iron atom). Glycine content per molecule is minor and nutritionally negligible at typical supplemental doses. The chelate bond protects Fe²⁺ from oxidation to Fe³⁺ in gastric acid, preserving the more bioavailable ferrous form. Bioavailability is estimated at 2-4x greater than ferrous sulfate in comparative studies, with relative bioavailability values reported between 100-174% compared to ferrous sulfate as reference standard. Absorption occurs via intestinal peptide transport pathways (PepT1) rather than competing with free iron DMT-1 transporters, reducing competitive inhibition. No vitamins, fiber, or other micronutrients are present. Contains no calories. The low molecular weight of ~204 Da facilitates intact mucosal cell uptake. Solubility is maintained across a broad gastric pH range, unlike inorganic iron salts that precipitate at higher pH levels.

Preparation & Dosage

The research does not specify clinically studied dosage ranges for iron bisglycinate chelate. While sources confirm its use in supplements and food enrichment for treating iron deficiency, specific dosing recommendations are not provided. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Folic acid, Vitamin B12, Copper, Vitamin A

Safety & Interactions

Iron bisglycinate chelate is generally well tolerated, with clinical studies reporting substantially fewer gastrointestinal side effects — including nausea, constipation, and epigastric discomfort — compared to ferrous sulfate, largely due to its lower mucosal reactivity and reduced luminal free iron. It can interact with fluoroquinolone and tetracycline antibiotics, levodopa, levothyroxine, and methyldopa by reducing their absorption; these medications should be separated by at least two hours. Concurrent antacid or proton pump inhibitor use may slightly reduce overall iron absorption, though the chelate form is more resistant to pH-dependent degradation than inorganic salts. Iron bisglycinate is considered safe during pregnancy at standard supplemental doses (14–27 mg elemental iron daily) and is commonly used in prenatal formulas, but excessive intake above the tolerable upper intake level of 45 mg elemental iron per day in adults may cause oxidative stress and gastrointestinal toxicity.